Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

ML-3000 enters phase III trial in osteoarthritis

April 25, 2000

C5 proven necessary for active arthritis; data support development of 5G1.1

April 25, 2000

Long-term outcomes show good safety profile for Celebrex

April 25, 2000

Corixa receives milestone from Organon for RA collaboration

April 24, 2000

Florida A&M's novel nonsteroidal antiinflammatory agents inhibit NO production

April 20, 2000

Nitro derivative of prednisolone, presented this week, possesses superior antiinflammatory activity

April 19, 2000

Patent issued to University of Rochester, setting off heated debate over rights to COX-2 inhibitors

April 18, 2000

FDA approves Mobic for osteoarthritis symptom relief

April 18, 2000

Corixa receives U.S. patent on RA vaccine

April 18, 2000

Enbrel recommended by FDA advisory committee for early RA

April 17, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...